| Literature DB >> 35282559 |
William N Duggar1, Bart Morris1, Rui He1, Claus Chunli Yang1.
Abstract
Objective The objective is to explore the possibility of optimal/rational application of setup margin during treatment planning for frameless stereotactic Gamma Knife radiosurgery/therapy. Methods Uncertainty measurements for frameless Gamma Knife Icon treatment were used to calculate the necessary setup margin via four different published recipes and these margins were subsequently applied to treatment plans of 30 previously treated patients and replans were generated meeting comparable plan quality metrics. All plans were then analyzed based on the ability to maintain normal tissue dose tolerances and the relative increase in target dose coverage probability using a pass/fail scoring system based on published normal tissue dose constraints and an in-house developed optimal scoring method. Results Gross tumor volume/planning target volume (GTV/PTV) size strongly correlated with both meeting normal tissue tolerances and optimal scores for single fraction plans corroborating published clinical outcomes. The Van Herk Margin Formula (VHMF) and Parker margin formulae were indicated as good candidates for high probabilities of both meeting normal tissue goals and high optimal scores which generally translated to just over 1 mm in GTV to PTV margin. Conclusion For single fraction treatment, GTV size is highly significant in predicting failure to meet normal tissue goals whereas whether setup margin was used was not a significant predictor. Setup margin can rationally be applied when fraction number is dictated by clinically indicated metrics regarding GTV size of greater or less than 4 cc. 1 mm is a reasonable practical application of margin added to GTV to ensure physical prescription dose target coverage for most cases when clinically desired based on disease type and intended outcome.Entities:
Keywords: frameless radiosurgery; gamma knife icon; ptv; rational margin; setup margin
Year: 2022 PMID: 35282559 PMCID: PMC8906882 DOI: 10.7759/cureus.21996
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Margin recipes to be used in this study
*Using effective values of Σ, σ [13,20]
**Simplified formula [16,18]
Prescription radiation dose is abbreviated as "Rx" above
| Recipe | Authors | Types of Uncertainty | Fraction Number | Target Type | CTV Coverage | Formula |
| ICRU | ICRU [ | Systematic and Random | Not Defined | Not Defined | Not Defined | √(Sys2+Rand2) |
| VHMF Mod* | Van Herk et al. [ | Systematic and Random | ≥ 1 | Prostate | 95% of Rx for 90% of patients | 2.5 Σeff + 1.64 (σeff-σp) |
| Zhang | Zhang et al. [ | Systematic and Residual | 1 | Brain Metastasis | 100% of Rx for 95% of patients | 2.787β** |
| Parker | Parker et al. [ | Systematic and Random | 5 to 30 | Cranial Targets | 95% of Rx for 99% of patients | Systematic + 1Σ + 1σ |
Normal tissue constraints utilized in the evaluation of all treatment plans
aThe brain volume constraint listed is per lesion, the volume increases to 30 cc for multi-lesion plans
bThe volume dose is marginal for multi-fraction but includes gross tumor volume (GTV) for single fraction regimens
Refs. [21-24]
| Normal Tissue Constraints (Doses in Gy) | ||||||||
| Single Fraction | 3 Fractions | 4 Fractions | 5 Fractions | |||||
| Structure | Volume | Max | Volume | Max | Volume | Max | Volume | Max |
| Braina | V12<10cc | None | V16.5<20ccb | None | V18.4<20ccb | None | V20<20ccb | None |
| Brainstem | V10<0.5cc | 15 | V18<0.5cc | 23.1 | V20.5<0.5cc | 27 | V23<0.5cc | 31 |
| Cord | V10<0.35cc | 15 | V18<0.35cc | 23.1 | V22<0.35cc | 26.5 | V26<0.35cc | 30 |
| Optics | V8<0.2cc | 12 | V15.3<0.2cc | 20 | V19<0.2cc | 22.5 | V23<0.2cc | 25 |
| Cochleae | None | 9 | None | 17.1 | None | 21 | None | 25 |
Summary of how treatment plans were scored after the use of each margin formula
*Target Coverage Score negated to zero based on any normal tissue dose failure
| Optimal Margin Scoring System | ||
| Category | Plan Value | Scoring |
| Target Coverage | 0, 1, 2, 3, 4 | + Value x 10 |
| Brain Dose Volume | Per cc over 10 cc (20 cc for Multi-Fx lesions) | - 10 |
| > 10cc (20 cc for Multi-Fraction lesions) | - Target Coverage Score* | |
| < 10 cc (20 cc for Multi-Fraction lesions) | 0 | |
| < 8.4 cc (16.8 cc for Multi-Fraction lesions) | + 10 | |
| < 7.9 cc (15.8 cc for Multi-Fraction lesions) | + 20 | |
| Brainstem, Cord, Chiasm, and Optic Nerves | Max Dose > table | - Target Coverage Score* |
| Max dose < table | 0 | |
| Max dose < table | + 10 | |
| Cochleae | Max Dose > table | - Target Coverage Score* |
| Max dose < table | 0 | |
Calculation of direction-dependent setup margins and relevant values
Fraction is abbreviated as “Fx” in some instances within the table
| X (mm) | Y (mm) | Z (mm) | ||
| Systematic Error Mean | 0.25 | 0.34 | 0.48 | |
| Systematic Error Standard Deviation (SD) | 0.43 | 0.47 | 0.44 | |
| Effective Systematic SD | 1 Fx | 0.54 | 0.57 | 0.64 |
| 3 Fx | 0.47 | 0.50 | 0.52 | |
| 4 Fx | 0.46 | 0.49 | 0.50 | |
| 5 Fx | 0.45 | 0.49 | 0.49 | |
| Random/Residual Error Mean | 0.02 | 0.06 | 0.26 | |
| Random/Residual Error SD | 0.33 | 0.32 | 0.45 | |
| Effective Random/Residual SD | 1 Fx | 0.00 | 0.00 | 0.00 |
| 3 Fx | 0.27 | 0.26 | 0.37 | |
| 4 Fx | 0.29 | 0.28 | 0.39 | |
| 5 Fx | 0.30 | 0.29 | 0.41 | |
| Penumbra (45-25%)* | 1.13 | 1.13 | 0.53 | |
| ICRU | 0.54 | 0.57 | 0.64 | |
| VHMF 1 Fraction | 1.35 | 1.42 | 1.59 | |
| VHMF 3 Fractions | 1.17 | 1.25 | 1.29 | |
| VHMF 4 Fractions | 1.14 | 1.23 | 1.25 | |
| VHMF 5 Fractions | 1.13 | 1.22 | 1.22 | |
| Parker | 1.01 | 1.13 | 1.37 | |
| Zhang 1D | 1.40 | 1.52 | 1.79 | |
Summary of treatment plan analysis for each margin recipe and original plans (n = 150 plans)
| Normal Tissue Dose Exceeded | Optimal Score | |||||||
| No | Yes | Total Plans | Mean | Min | Max | St. Dev. | ||
| Setup Margin Recipe | None | 27 | 3 | 30 | 52.3 | 0 | 60 | 15.2 |
| ICRU | 25 | 5 | 30 | 58.3 | 0 | 70 | 19 | |
| VHMF | 22 | 8 | 30 | 61 | 0 | 90 | 32.2 | |
| Parker | 22 | 8 | 30 | 62.7 | 0 | 90 | 29.5 | |
| Zhang | 19 | 11 | 30 | 65 | 0 | 100 | 39.8 | |
All moderate to strong relationships identified to be statistically significant in correlation analysis after margin application in various scenarios (no significant relationships found in correlation for multi-fraction, pass/fail)
| Scenario | Variable | Coefficient | p-value | Strength | Significant | 95% CI | N | ||
| All Plans, Pass/Fail | Number of Fractions | -0.398 | < 0.001 | Moderate | Highly | -0.525, -0.254 | 150 | ||
| All Plans, Optimal Score | Patient Head Lateral Diameter | -0.321 | < 0.001 | Moderate | Highly | -0.458, -0.169 | 150 | ||
| Number of Fractions | 0.362 | < 0.001 | Moderate | Highly | 0.214, 0.494 | 150 | |||
| Single Fraction, Pass/Fail | Patient Weight | 0.338 | 0.002 | Moderate | Yes | 0.128, 0.519 | 80 | ||
| Patient Head Lateral Diameter | 0.4 | < 0.001 | Moderate | Highly | 0.198, 0.570 | 80 | |||
| Number of Targets | -0.352 | 0.001 | Moderate | Yes | -0.531, -0.143 | 80 | |||
| Number of Central Targets | -0.411 | < 0.001 | Moderate | Highly | -0.578, -0.210 | 80 | |||
| Largest GTV Volume | 0.541 | < 0.001 | Strong | Highly | 0.365, 0.680 | 80 | |||
| Total GTV Volume | 0.504 | < 0.001 | Strong | Highly | 0.320, 0.652 | 80 | |||
| Total PTV Volume | 0.528 | < 0.001 | Strong | Highly | 0.349, 0.670 | 80 | |||
| Single Fraction, Optimal Score | Patient Weight | -0.369 | 0.001 | Moderate | Yes | -0.545, -0.162 | 80 | ||
| Patient Head Lateral Diameter | -0.463 | < 0.001 | Moderate | Highly | -0.620, -0.271 | 80 | |||
| Number of Targets | 0.376 | 0.001 | Moderate | Yes | 0.170, 0.550 | 80 | |||
| Number of Peripheral Targets | 0.300 | 0.007 | Moderate | Yes | 0.086, 0.488 | 80 | |||
| Number of Central Targets | 0.402 | < 0.001 | Moderate | Highly | 0.200, 0.571 | 80 | |||
| Largest GTV Volume | -0.662 | < 0.001 | Strong | Highly | -0.770, -0.518 | 80 | |||
| Total GTV Volume | -0.644 | < 0.001 | Strong | Highly | -0.757, -0.494 | 80 | |||
| Total PTV Volume | -0.613 | < 0.001 | Strong | Highly | -0.734, -0.454 | 80 | |||
| Multi-Fraction, Optimal Score | Patient Weight | -0.349 | 0.003 | Moderate | Yes | -0.540, -0.124 | 70 | ||
| Patient BMI | -0.373 | 0.001 | Moderate | Yes | -0.559, -0.151 | 70 | |||
| Average Sphericity (Equivalent Sphere/Max Diameter) | 0.34 | 0.004 | Moderate | Yes | 0.114, 0.532 | 70 | |||
Figure 1Plots of largest GTV volume and total PTV volume versus Pass/Fail (Normal Tissue Dose Exceeded). A distinction can be seen at 4 cc and 5 cc for the GTV and PTV, respectively.